The Global HIV Vaccine Enterprise

The Global HIV Vaccine Enterprise
Uniting stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of—and future access to—an HIV vaccine

Learn more Strategic Plan

A renewed Strategic Plan

Uniting stakeholders to share knowledge, foster collaboration, enable solutions and to support the most critical issues, risks and challenges faced by the field

Increasing resources

Mobilizing new funding to support and grow the field of HIV vaccine research and development

Greater collaboration

Promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts

BACK TO THE FUTURE: HIV VACCINE LEARNINGS

26 May 2021

An event to engage scientists, clinicians, industry, funders, and community representatives on how best to learn from past efficacy trials to inform future vaccine development efforts.

Presentations available online

DESIGN APPROACHES FOR CURRENT AND FUTURE HIV PREVENTION EFFICACY TRIALS

VIRTUAL WORKSHOP SERIES

October 2020 to May 2021

Presentations and panel discussions 1-3 available online

Find out more

News

IAS statement: Imbokodo trial must compel us to adequately resource efforts to find an HIV vaccine

September 1, 2021/in News /by noura elrassi

Yesterday Johnson and Johnson and its global partners announced that they would discontinue the large-scale Imbokodo HIV Vaccine Trial. Initial results showed that the vaccine did not provide significant protection against HIV infection in young women in sub-Saharan Africa. Despite this disappointing news, IAS – the International AIDS Society – emphasizes the importance of continued investment […]

26 MAY 2021 – BACK TO THE FUTURE: HIV VACCINE LEARNINGS

May 18, 2021/in Events /by Roger Tatoud

An event to engage scientists, clinicians, industry, funders, and community representatives on how best to learn from past efficacy trials to inform future vaccine development efforts.

Timely topics

In 2012, the Enterprise launched Timely Topics in HIV Vaccines, a strategy series convening experts as rapidly as possible to analyze, address, and respond to unresolved and emerging priority issues in the field. Through an open call for proposals, the Enterprise is working to identify the most important strategic needs of the field and sponsoring think tanks, meetings, forums and other events to tackle these issues.

Submit a timely topic